Perez, E. A., Dueck, A. C., McCullough, A. E., Reinholz, M. M., Tenner, K. S., Davidson, N. E., . . . Chen, B. (2012). Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. Oxford University Press.
Chicago ZitierstilPerez, Edith A., et al. Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. Oxford University Press, 2012.
MLA ZitierstilPerez, Edith A., et al. Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. Oxford University Press, 2012.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.